Drugs Containing Excipient (Inactive Ingredient) GELATIN

Branded drugs containing GELATIN excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	STRATTERA	atomoxetine hydrochloride	0002-3227	GELATIN
Eli Lilly and Company	SYMBYAX	olanzapine and fluoxetine hydrochloride	0002-3230	GELATIN
Eli Lilly and Company	SYMBYAX	olanzapine and fluoxetine hydrochloride	0002-3231	GELATIN

Generic drugs containing GELATIN excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	atomoxetine hydrochloride	0002-3227	GELATIN
Eli Lilly and Company	olanzapine and fluoxetine hydrochloride	0002-3230	GELATIN
Eli Lilly and Company	olanzapine and fluoxetine hydrochloride	0002-3231	GELATIN

Market Dynamics and Financial Trajectory for Gelatin in the Pharmaceutical Excipients Sector

Last updated: February 20, 2026

What are the key drivers influencing the gelatin market in pharmaceuticals?

The global pharmaceutical excipients market, specifically gelatin, is expanding. The driving factors include:

• Increasing demand for biologics and vaccines that utilize gelatin in capsule manufacturing.
• Growing awareness of natural and biodegradable excipients among pharmaceutical companies.
• Rising investments in vaccine development, which rely heavily on gelatin-based capsules and stabilizers.
• Regulatory recognition of gelatin as a safe, biodegradable excipient with established safety profiles.

How does the supply chain impact gelatin's market growth?

The supply chain's stability critically influences market dynamics:

• Major sourcing from countries like China, Brazil, and India, which control approximately 80% of global gelatin production (UNIDO, 2021).
• Fluctuations in raw material availability, mostly collagen from bovine and porcine sources, influence pricing.
• COVID-19 disruptions caused temporary shortages and increased prices by an average of 15–20% in 2020–2021.

What are the technological innovations shaping market competitiveness?

Innovations include:

• Development of vegetarian gelatin alternatives, such as plant-based hydrocolloids.
• Improvements in capsule manufacturing that extend shelf life and enhance bioavailability.
• Enhanced sterilization and processing methods ensuring purity and safety standards.

What are the financial estimates for gelatin in pharmaceutical applications?

Market size and growth projections:

Year	Market Size (USD billion)	Compound Annual Growth Rate (CAGR)	Source
2022	0.85	6.5%	[1]
2027	1.2	6.8%	[1]

The market is expected to grow from USD 0.85 billion in 2022 to USD 1.2 billion by 2027. Growth is driven by increased vaccine production and expanding pharmaceutical capsule use.

How do regulatory policies impact gelatin market dynamics?

Regulators enforce strict standards:

• USP and EP standards classify gelatin as a pharmaceutic aid.
• The European Medicines Agency (EMA) and FDA mandate transparency regarding raw material sources.
• Legislation favoring vegetarian and synthetic alternatives could restrain gelatin's growth.

What are the competitive landscape considerations?

Leading companies include:

• Rousselot (Arborea)
• Gelatin Enterprises Inc.
• Nippi Inc.
• Weishardt Group

Market shares vary regionally, with Asia-Pacific companies collectively holding approximately 60% of global capacity. The competitive focus involves price, quality, and source transparency.

What are the future growth opportunities and risks?

Opportunities:

• Expansion into emerging markets with rising healthcare access.
• Development of allergen-free and vegetarian gelatin alternatives.
• Customization of gelatin properties for targeted drug delivery.

Risks:

• Regulatory shifts favoring synthetic alternatives.
• Raw material price volatility.
• Ethical concerns impacting bovine/porcine sourcing.

Key Takeaways

The gelatin market within pharmaceutical excipients is experiencing steady growth, underpinned by vaccine demand, natural product preferences, and technological innovations. Supply chain dependencies and regulatory policies remain critical to market stability. Companies focusing on source transparency and alternative sources will be better positioned in a competitive landscape that favors sustainable and ethical practices.

FAQs

1. What is the primary application of gelatin in pharmaceuticals? Gelatin is mainly used for capsule shells, vaccines, and as a stabilizer or binder in drug formulations.

2. Which regions are leading in gelatin pharmaceutical production? Asia-Pacific accounts for over 60% of global capacity, with notable contributions from China, India, and Brazil.

3. How does gelatin pricing trend affect pharmaceutical affordability? Price fluctuations influence manufacturing costs, which can lead to higher drug prices or supply shortages.

4. Are there alternatives to gelatin for pharmaceutical applications? Yes. Plant-based hydrocolloids like hydroxypropyl methylcellulose (HPMC) are emerging as alternatives, especially in vegetarian products.

5. What regulatory challenges could impact gelatin usage? Increasing scrutiny over animal-derived products and shifts toward synthetic or plant-based excipients could restrict gelatin's market share.

---

References

[1] MarketsandMarkets. (2022). Pharmaceutical Excipient Market by Type (Lactose, Microcrystalline Cellulose, Gelatin), Application, Region — Global Forecast to 2027.